非奈利酮对心力衰竭患者肾脏结局的影响:FINEARTS-HF 试验
FINEARTS-HF 试验的预设分析评估非奈利酮对射血分数轻度降低或保留的心衰患者肾脏结局的影响。在 6001 例受试者中,非奈利酮未显著改变 eGFR 持续下降≥50% 或肾衰竭的复合肾脏结局(HR 1.33,95%CI 0.94-1.89),但早期 eGFR 下降更明显,慢性 eGFR 斜率无显著差异,并显著降低白蛋白尿及新发微量/大量白蛋白尿风险。
要点
- 非奈利酮未显著改变复合肾脏结局风险(HR 1.33,95%CI 0.94-1.89)。
- 非奈利酮早期 eGFR 下降更明显(-2.9 mL/min/1.73 m²),但慢性 eGFR 斜率无显著差异。
- 非奈利酮降低 UACR 30%,并减少新发微量及大量白蛋白尿风险。
核心结论
- 在肾脏不良结局风险较低的心衰人群中,非奈利酮未显著改变肾脏复合结局。
- 非奈利酮导致初始 eGFR 下降更明显,但未显著改变慢性 eGFR 斜率。
- 非奈利酮早期且持续降低白蛋白尿,并减少新发微量及大量白蛋白尿风险。
研究设计与样本
- FINEARTS-HF 试验的预设分析,随机对照试验,比较非奈利酮与安慰剂。
- 纳入 6001 例射血分数轻度降低或保留的心衰患者,平均基线 eGFR 62±20 mL/min/1.73 m²,48% 患者 eGFR<60 mL/min/1.73 m²。
- 5797 例有基线 UACR 数据,中位 UACR 18 mg/g(Q1-Q3:7-67 mg/g),中位随访 2.6 年。
主要发现
- 复合肾脏结局(eGFR 持续下降≥50% 或肾衰竭)发生率非奈利酮组 vs 安慰剂组:75 vs 55 事件,HR 1.33(95%CI 0.94-1.89),无统计学显著性。
- eGFR 持续下降≥57% 或肾衰竭复合结局:41 vs 31 事件,HR 1.28(95%CI 0.80-2.05)。
- 前 3 个月非奈利酮组 eGFR 急性下降 -2.9 mL/min/1.73 m²(95%CI -3.4 至 -2.4),慢性(3 个月起)eGFR 斜率差异 +0.2 mL/min/1.73 m²/年(95%CI -0.1 至 0.4)。
- 总斜率差异 -0.7 mL/min/1.73 m²/年(95%CI -0.9 至 -0.4)。
- 非奈利酮组 6 个月内 UACR 降低 30%(95%CI 25%-34%),持续整个随访期;新发微量白蛋白尿风险降低 24%(HR 0.76,95%CI 0.68-0.83),新发大量白蛋白尿风险降低 38%(HR 0.62,95%CI 0.53-0.73)。
临床怎么用
- 对于射血分数轻度降低或保留的心衰患者,非奈利酮可考虑用于降低白蛋白尿及新发白蛋白尿风险。
- 使用非奈利酮时需关注早期 eGFR 下降,但不应因此停药,因慢性 eGFR 斜率无显著差异。
局限性
- 研究人群肾脏不良结局风险较低,事件频率相对较低,可能限制肾脏复合结局的统计效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Finerenone has kidney-protective effects in patients with chronic kidney disease with type 2 diabetes, but effects on kidney outcomes in patients with heart failure with and without diabetes and/or chronic kidney disease are not known. OBJECTIVES: The purpose of this study was to examine the effects of finerenone on kidney outcomes in FINEARTS-HF (Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure), a randomized trial of finerenone vs placebo among patients with heart failure with mildly reduced or preserved ejection fraction. METHODS: We explored the effects of finerenone on the secondary outcome of a sustained ≥50% estimated glomerular filtration rate (eGFR) decline or kidney failure (sustained eGFR decline <15 mL/min/1.73 m2; initiation of maintenance dialysis; renal transplantation). In this prespecified analysis, we also report effects of finerenone on: 1) sustained ≥57% eGFR decline or kidney failure; 2) eGFR slope; and 3) changes in urine albumin/creatinine ratio (UACR). RESULTS: Among 6,001 participants, mean baseline eGFR was 62 ± 20 mL/min/1.73 m2; 48% had eGFR <60 mL/min/1.73 m2. Overall, 5,797 had baseline UACR data (median: 18 mg/g [Q1-Q3: 7-67 mg/g]). Over 2.6 years median follow-up, the incidence of the composite kidney outcome (≥50% eGFR decline or kidney failure) was numerically, but nonsignificantly, higher for finerenone vs placebo (75 vs 55 events; HR: 1.33; 95% CI: 0.94-1.89). Similar results were observed for the composite of ≥57% eGFR decline or kidney failure (41 vs 31 events; HR: 1.28; 95% CI: 0.80-2.05), although the overall event frequency was relatively low. During the first 3 months, finerenone led to an acute decline in eGFR of -2.9 mL/min/1.73 m2 (95% CI: -3.4 to -2.4 mL/min/1.73 m2) but did not alter chronic (from 3 months) eGFR slope (+0.2 mL/min/1.73 m2 per year; 95% CI: -0.1 to 0.4 mL/min/1.73 m2 per year), vs placebo. The difference in total slope was -0.7 mL/min/1.73 m2 per year (95% CI: -0.9 to -0.4 mL/min/1.73 m2 per year.). Finerenone reduced UACR by 30% (95% CI: 25%-34%) over 6 months vs placebo, an effect that persisted throughout follow-up. Finerenone reduced the risk of new-onset of microalbuminuria and macroalbuminuria by 24% (HR: 0.76; 95% CI: 0.68-0.83) and 38% (HR: 0.62; 95% CI: 0.53-0.73), respectively. CONCLUSIONS: In FINEARTS-HF, a population at low risk of adverse kidney outcomes, finerenone did not significantly modify the kidney composite outcomes. Finerenone led to a greater reduction in initial eGFR, but did not result in a significant difference in chronic eGFR slope vs placebo. Finerenone led to early and sustained reductions in albuminuria and reduced the risk of new-onset micro- and macroalbuminuria. (FINEARTS-HF [Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenon on Morbidity (Events Indicating Disease Worsening) & Mortality (Death Rate) in Participants with Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%]; NCT04435626).
引用
- Mc Causland, Vaduganathan, Claggett, et al. Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF Trial. J Am Coll Cardiol. 2024. PMID: 39490700. doi:10.1016/j.jacc.2024.10.091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。